Obesity Cohort Bichat Louis Mourier (COBILOM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03538210|
Recruitment Status : Recruiting
First Posted : May 29, 2018
Last Update Posted : May 29, 2018
Obesity prevalence rapidly increased in the past decades in French population with multiple health consequences responsible for excess mortality. In the same period of time, the number of bariatric procedures have developed exponentially. Despite its great efficacy on weight loss but also on resolution of comorbidities, bariatric surgery is not without risks. Our hypothesis is that a better understanding of the physio-pathological consequences of obesity and bariatric surgery, notably on the gastrointestinal tract, may allow to improve the treatment of obesity and to find alternatives to bariatric surgery.
The main objective of this cohort study is to systematize the collection and the conservation of biological samples (blood, stomach, liver, intestine, adipose tissue) obtained during bariatric surgery, in obese subjects undergoing surgery (including sleeve gastrectomy, Roux-en-Y gastric bypass, or revisional intervention for complication or weight regain) in the University Hospital group of Paris Nord Val de Seine (HYPNVS).
The main projects that will build on this cohort will cover the physiopathology of obesity and its consequences, notably in the field of gastrointestinal tract including: modification of gastro-intestinal plasticity in severe obesity and after bariatric surgery and alterations of absorption of nutriments (lipids, proteins, carbohydrates) induced by obesity and bariatric surgery. The inclusion in this project of obese subjects before surgery, or lean or obese subjects after surgery will allow to distinguish the impact of weight loss and surgery on gastrointestinal remodeling. This cohort will also allow to characterize stomach and intestinal proteome in severe obesity and to precise the influence of tissue inflammation on metabolic disorders associated with obesity.
|Condition or disease|
|Severe Obesity Bariatric Surgery Surgical Failure|
|Study Type :||Observational|
|Estimated Enrollment :||420 participants|
|Official Title:||Cohorte Obésité Bichat LOuis Mourier|
|Actual Study Start Date :||February 16, 2018|
|Estimated Primary Completion Date :||June 16, 2020|
|Estimated Study Completion Date :||September 16, 2020|
- number of biological samples collected [ Time Frame: during surgery ]liver stomach and intestin samples will be performed during surgery for usual care. Adiposes tissues and blood samples will be performed for reseach, on the surgical site
- modifications of gastro-intestinal plasticity induces by obesity and bariatric surgery [ Time Frame: samples collected during surgery ]gene expression of basic helix-loop-helix transcription factors (fold increase as compared to control)
- alterations of absroption and metabolism of nutriments induced by obesity and bariatric surgery [ Time Frame: samples collected during surgery ]intestinal protein expression of monosaccharides, proteins, fatty acids and cholesterol transporters (fold increase as compare to control)
- gastric and intestinal proteome [ Time Frame: samples collected during surgery ]gastric and intestinal proteome in the obese morbid subject assessed by mass spectrometry
- tissue inflammation and fibrosis [ Time Frame: samples collected during surgery ]quantification of the inflammatory infiltrate of the visceral and subcutaneous adipose tissue, liver and intestine (number per area)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03538210
|Contact: Séverine LEDOUX, Md, PhD||147606256 ext +firstname.lastname@example.org|
|Contact: André BADO, PhDemail@example.com|